

Research article

Open Access

Lack of association between *PKLR* rs3020781 and *NOS1AP* rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits

Camilla Helene Andreassen^{*1,2}, Mette Sloth Mogensen¹, Knut Borch-Johnsen^{1,3,4}, Anelli Sandbæk⁵, Torsten Lauritzen⁵, Katrine Almind², Lars Hansen⁶, Torben Jørgensen^{3,7}, Oluf Pedersen^{1,4,7} and Torben Hansen^{1,8}

Address: ¹Steno Diabetes Center, 2820 Gentofte, Denmark, ²Novo Nordisk A/S, Medical and Science, Development Projects, 2880 Bagsværd, Denmark, ³Research Centre for Prevention and Health, Glostrup University Hospital, 2600 Glostrup, Denmark, ⁴Faculty of Health Science, University of Aarhus, 8000 Aarhus, Denmark, ⁵Department of General Practice, University of Aarhus, 8000 Aarhus, Denmark, ⁶Bristol-Meyers Squibb & Co, Discovery Medicine and Clinical Pharmacology, CV Metabolic Diseases, 08543-4000 Princeton NJ, USA, ⁷Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark and ⁸Faculty of Health Sciences, University of Southern Denmark, 5000 Odense, Denmark

Email: Camilla Helene Andreassen* - cila@novonordisk.com; Mette Sloth Mogensen - mmog@steno.dk; Knut Borch-Johnsen - kbjo@steno.dk; Anelli Sandbæk - ANNELLI.SANDBAEK@ALM.AU.DK; Torsten Lauritzen - TL@ALM.AU.DK; Katrine Almind - ktra@novonordisk.com; Lars Hansen - lars.hansen@bms.com; Torben Jørgensen - tojo@glo.regionh.dk; Oluf Pedersen - oluf@steno.dk; Torben Hansen - toha@steno.dk

* Corresponding author

Published: 26 December 2008

Received: 24 April 2008

BMC Medical Genetics 2008, 9:118 doi:10.1186/1471-2350-9-118

Accepted: 26 December 2008

This article is available from: <http://www.biomedcentral.com/1471-2350/9/118>

© 2008 Andreassen et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25. Both *PKLR* encoding the liver pyruvate kinase and *NOS1AP* encoding the nitric oxide synthase 1 (neuronal) adaptor protein (CAPON) are positioned within this chromosomal region and are thus positional candidates for the observed linkage peak. The C-allele of *PKLR* rs3020781 and the T-allele of *NOS1AP* rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16–1.54] and 1.53 [1.28–1.81], respectively. Our aim was to validate these findings by investigating the impact of the two variants on type 2 diabetes and related quantitative metabolic phenotypes in a large study sample of Danes. Further, we intended to expand the analyses by examining the effect of the variants in relation to overweight and obesity.

Methods: *PKLR* rs3020781 and *NOS1AP* rs7538490 were genotyped, using TaqMan allelic discrimination, in a combined study sample comprising a total of 16,801 and 16,913 individuals, respectively. The participants were ascertained from four different study groups; the population-based Inter99 cohort ($n_{PKLR} = 5,962$, $n_{NOS1AP} = 6,008$), a type 2 diabetic patient group ($n_{PKLR} = 1,873$, $n_{NOS1AP} = 1,874$) from Steno Diabetes Center, a population-based study sample ($n_{PKLR} = 599$, $n_{NOS1AP} = 596$) from Steno Diabetes Center and the ADDITION Denmark screening study cohort ($n_{PKLR} = 8,367$, $n_{NOS1AP} = 8,435$).

Results: In case-control studies we evaluated the potential association between rs3020781 and rs7538490 and type 2 diabetes and obesity. No significant associations were observed for type 2 diabetes (rs3020781: $p_{AF} = 0.49$, OR = 1.02 [0.96–1.10]; rs7538490: $p_{AF} = 0.84$, OR = 0.99 [0.93–1.06]). Neither did we show association with overweight or obesity. Additionally, the *PKLR* and the *NOS1AP* genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes.

Conclusion: We failed to provide evidence of an association between *PKLR* rs3020781 and *NOS1AP* rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.

Background

Type 2 diabetes (T2D) is a complex metabolic disease, where several tissues and organs, including pancreatic β -cells, skeletal muscle, adipose tissue, liver and the central nervous system have been suggested to be directly or indirectly involved in the pathogenesis [1].

Several independent studies have shown evidence for linkage between chromosome 1q21-25 and T2D in multiple ethnicities [2-14]. Both *PKLR* encoding the liver pyruvate kinase and *NOS1AP* encoding the nitric oxide synthase 1 (neuronal) adaptor protein (CAPON), are located in the 1q21-25 region and are therefore positional candidate genes for T2D susceptibility. The pyruvate kinase enzyme catalyses the last step in glycolysis converting phosphoenolpyruvate to pyruvate under the generation of ATP. *PKLR* is, in addition to the liver, expressed in pancreatic β -cells, the kidneys and the small intestine [15], and its expression is upregulated by glucose through a carbohydrate response element in the promoter [16]. Moreover, a binding site for hepatocyte nuclear factor 1- α is located in the *PKLR* promoter and patients with maturity-onset diabetes of the young type 1 and 3 show decreased expression of the gene [17,18]. Hence, *PKLR* is a strong biological candidate gene for impaired blood glucose regulation and thus T2D. The CAPON protein binds nitric oxide synthase, which results in downregulation of N-methyl-D-aspartate receptor-mediated glutamate signalling [19], however, the link between dysfunctional CAPON protein and T2D is as yet unexplained.

A substantial number of genes, in this very gene-dense 1q21-25 region, have already been investigated for susceptibility to T2D, however, none have so far explained the observed linkage [1]. As a part of The International Type 2 Diabetes 1q Consortium 5,285 single-nucleotide polymorphisms (SNPs), covering 22.7 Mb of the 1q linkage region were genotyped in 1,000 cases and 1,198 matched controls from four different European-descent populations.

Two SNPs, rs3020781 in *PKLR* and rs7538490 in *NOS1AP* were reported to associate with T2D. Applying an additive

model the C-allele of *PKLR* rs3020781 associated with T2D with an odds ratio (OR) of 1.33 [1.16–1.54] ($p = 1 \cdot 10^{-6}$), and under a dominant model the T-allele of *NOS1AP* rs7538490 associated with T2D with an OR of 1.53 [1.28–1.81] ($p = 2 \cdot 10^{-6}$)[38]. *PKLR* has previously been examined in two independent studies, where four SNPs, (rs3020781, rs2071053, rs1052176, rs1052177), showed association with T2D when analysing a total 909 individuals of European descent [20,21]. No further association studies regarding the role of *NOS1AP* in T2D pathogenesis have been performed.

The aim of the present study was to validate the association of *PKLR* rs3020781 and *NOS1AP* rs7538490 with T2D. In addition we intend to expand with analyses of overweight and obesity and the relationship with diabetes-related metabolic quantitative phenotypes.

Methods

Subjects

PKLR rs3020781 and *NOS1AP* rs7538490 were successfully genotyped in 16,801 and 16,913 Danes, respectively, involving four study groups 1) the population-based Inter99 cohort (ClinicalTrials.gov ID no: NCT00289237) ($n_{PKLR} = 5,962$, $n_{NOS1AP} = 6,008$), with an average age of 46 ± 8 years and a mean BMI of 26.2 ± 4.6 kg/m², sampled at the Research Centre for Prevention and Health [22] 2) unrelated T2D patients ($n_{PKLR} = 1,873$, $n_{NOS1AP} = 1,874$), with an average age of 62 ± 11 years and a mean BMI of 30.0 ± 5.6 kg/m², sampled through the out-patient clinic at Steno Diabetes Center 3) a population-based group of unrelated middle-aged individuals ($n_{PKLR} = 599$, $n_{NOS1AP} = 596$), with an average age of 59 ± 8 years and a mean BMI of 26.5 ± 4.2 kg/m², examined at Steno Diabetes Center 4) the ADDITION Denmark screening study cohort (ClinicalTrials.gov ID no: NCT00237548) ($n_{PKLR} = 8,367$, $n_{NOS1AP} = 8,435$), with an average age of 60 ± 7 years and a mean BMI of 28.6 ± 4.9 kg/m², sampled by Department of General Practice at University of Aarhus [23]. The different study groups are further described in Additional file 1. In study group 1 and 3 all non-diabetic individuals underwent a standard 75 g oral glucose tolerance test (OGTT) and only glucose-tolerant and normoglycaemic

individuals were included as control subjects in the case-control study of T2D. Analyses of quantitative metabolic phenotypes were performed in the population-based Inter99 cohort exclusively, excluding T2D patients receiving pharmacological treatment. Informed written consent was obtained from all individuals before participation. The studies were approved by the regional Ethical Committees (Ethics Committee, Copenhagen County for study group 1, 2 and 3 and Ethics Committee, Aarhus County for study group 4) and were in accordance with the principles of the *Helsinki Declaration*. T2D and normal glucose tolerance (NGT) were defined according to the World Health Organization [24].

Biochemical and anthropometrical measurements

In all study groups body weight and height were measured in light indoor clothes and without shoes [22,23]. In study groups 1 and 3 serum insulin and plasma glucose were measured at fasting and 30 and 120 minutes after an OGTT. Serum insulin levels excluding des(31,32)- and intact proinsulin were measured using the AutoDELFA insulin kit (Perkin-Elmer, Wallac, Turku, Finland). Plasma glucose was analysed using a glucose oxidase method (Granustest; Merck, Darmstadt, Germany) [25]. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as fasting plasma glucose (mmol/l) multiplied by fasting serum insulin (pmol/l) divided by 22.5. The BIGTT insulin sensitivity index (BIGTT-S_i) and BIGTT acute insulin response (BIGTT-AIR) were calculated as described [26,27].

Genotyping

PKLR rs3020781 and *NOS1AP* rs7538490 were genotyped using Taqman allelic discrimination (KBioscience, Herts, UK). Discordances between 1,202 random duplicate samples were 0.1% and 0.2%, respectively, and the genotyping success rates were 96.3% and 96.8%, respectively. Both genotype groups obeyed Hardy-Weinberg equilibrium ($p > 0.05$).

Statistical analysis

Fisher's exact test was applied to examine differences in allele frequencies (AF) between affected and unaffected individuals. A general linear model was used to test quantitative metabolic variables for differences between genotype groups assuming an additive (Add) model for *PKLR* rs3020781, and a dominant (Dom) model for *NOS1AP* rs7538490. Values of plasma glucose, serum insulin, HOMA-IR and BIGTT-AIR were logarithmically transformed before statistical analysis to obtain normal distribution. Adjustment for sex, age and BMI was applied when appropriate. All analyses were performed in RGui version 2.5.0 [28], and p -values < 0.05 were considered significant. Statistical power was determined using the CaTS power calculator version 0.0.2. A test for homogeneity

between the population-based Inter99 cohort, the T2D patients and the population-based sample from Steno Diabetes Center and the ADDITION Denmark screening study cohort, was performed by means of the Mantel-Haenszel method (fixed effects model) for both genotypes, revealing no significant heterogeneity between study groups (rs3020781: $p = 0.8$, rs7538490: $p = 0.4$).

Results and discussion

The minor allele frequencies (MAF) of the *PKLR* rs3020781 C-allele and the *NOS1AP* rs7538490 T-allele were 26.2% and 28.0%, respectively, and comparable to the 32.5% and 29.7%, reported for the HapMap CEU population. Using the population-based Inter99 cohort as reference the prevalence of T2D is estimated to 6% in the Danish population of middle-aged people. Combining the four study samples, gives us a statistical power of 100% observing an association with T2D with a relative risk above 1.3, and a MAF as reported for the two variants assuming either an additive or a dominant model. The potential associations between *PKLR* rs3020781 and *NOS1AP* rs7538490 and T2D were evaluated in case-control studies including 8,410 and 8,447 individuals, respectively. No difference in allele frequencies between T2D patients and glucose-tolerant subjects were found for either SNP (rs3020781: $p_{AF} = 0.49$, OR [95% CI] = 1.02 [0.96–1.10]; rs7538490: $p_{AF} = 0.84$, OR [95% CI] = 0.99 [0.93–1.06]), Table 1.

Case-control studies comparing allele frequencies between body mass index (BMI) defined normal weight (BMI < 25 kg/m²) individuals and overweight (25 kg/m² \leq BMI < 30 kg/m²) or obese (BMI ≥ 30 kg/m²) individuals, respectively, were performed in the combined study sample including T2D patients. No statistically significant association with overweight or obesity were demonstrated for *PKLR* rs3020781 (overweight: $p_{AF} = 0.49$, OR [95% CI] = 0.98 [0.92–1.04]; obesity: $p_{AF} = 0.81$, OR [95% CI] = 0.99 [0.93–1.06]) nor for *NOS1AP* rs7538490 (overweight: $p_{AF} = 0.48$, OR [95% CI] = 0.95 [0.83–1.09]; obesity: $p_{AF} = 0.68$, OR [95% CI] = 0.99 [0.93–1.05]), Table 1. As pharmacological treatment can influence on BMI, we additionally performed case-control studies of overweight and obesity considering T2D patients and treatment-naïve individuals separately, however, neither variant showed association with overweight or obesity when stratifying according to glucose tolerance status (data not shown).

Furthermore, we investigated *PKLR* rs3020781 and *NOS1AP* rs7538490 for influence on diabetes-related quantitative metabolic phenotypes in 5,590 and 5,630 treatment-naïve Danish people from the population-based Inter99 cohort, respectively. No association with plasma glucose or serum insulin levels at fasting, 30 or 120 min during an OGTT or with OGTT-derived surrogate

Table 1: Case-control studies of PKLR rs3020781 and NOS1AP rs7538490 in relation to type 2 diabetes, overweight and obesity

PKLR rs3020781							
	<i>n</i> (men/women)	TT (%)	TC (%)	CC (%)	MAF (95% CI)	<i>p</i> _{AF}	OR (95% CI)
NGT	4,736 (2,209/2,527)	2,602 (55)	1,812 (38)	322 (7)	25.9 (25.0–26.8)	0.49	1.02 (0.96–1.10)
T2D	3,674 (2,187/1,487)	1,998 (54)	1,412 (39)	264 (7)	26.4 (25.4–27.4)		
BMI < 25 (kg/m²)	5,036 (2,111/2,925)	2,732 (54)	1,952 (39)	352 (7)	26.4 (25.5–27.2)		
25 ≤ BMI < 30 (kg/m²)	6,985 (4,359/2,626)	3,821 (55)	2,700 (39)	464 (6)	26.0 (25.2–26.7)	0.49	0.98 (0.92–1.04)
BMI ≤ 30 (kg/m²)	4,780 (2,467/2,313)	2,612 (55)	1,845 (38)	323 (7)	26.2 (25.3–27.1)	0.81	0.99 (0.93–1.06)
NOS1AP rs7538490							
	<i>n</i> (men/women)	CC (%)	CT (%)	TT (%)	MAF (95% CI)	<i>p</i> _{AF}	OR (95% CI)
NGT	4,755 (2,218/2,537)	2,479 (52)	1,914 (40)	362 (8)	27.7 (26.8–28.7)	0.84	0.99 (0.93–1.06)
T2D	3,692 (2,200/1,492)	1,954 (53)	1,439 (39)	299 (8)	27.6 (26.6–28.6)		
BMI < 25 (kg/m²)	5,064 (2,128/2,936)	2,635 (52)	2,013 (40)	416 (8)	28.1 (27.2–29.0)		
25 ≤ BMI < 30 (kg/m²)	7,030 (4,384/2,646)	3,628 (51)	2,857 (41)	545 (8)	28.1 (27.3–28.8)	0.48	0.95 (0.83–1.09)
BMI ≥ 30 (kg/m²)	4,819 (2,490/2,329)	2,517 (52)	1,923 (40)	379 (8)	27.8 (26.9–28.7)	0.68	0.99 (0.93–1.05)

Data are number of individuals, divided into genotype groups (% in each group), and frequencies of the minor allele (MAF) in percentages. Fisher's exact test was used to compare allele frequencies (*p*_{AF}). The odds ratios (OR) and 95% confidence interval (CI) are given for comparison of allele frequency. NGT: individuals with normal glucose tolerance, T2D: type 2 diabetic patients.

indices of insulin sensitivity or beta-cell function was demonstrated, Table 2. To evaluate the effect of the variants in individuals without impaired blood glucose regulation, analyses of quantitative metabolic phenotypes were conducted in the population-based Inter99 cohort including only glucose-tolerant individuals (*n*_{PKLR} = 4,248, *n*_{NOS1AP} = 4,269). However, no significant differences in genotype distribution of the two SNPs were demonstrated (data not shown).

Despite successful identification of several T2D susceptible genes only a small percentage of T2D heritability is explained, thus, more T2D genes are to be found.

Originally two clusters of SNPs located within the T2D linkage peak were identified by The International Type 2 Diabetes 1q Consortium to associate with T2D among a total of 5,285 SNPs tagging the linkage peak. The first cluster of 9 SNPs were located in a linkage disequilibrium (LD) region including PKLR while the second cluster of 4 SNPs resided within NOS1AP. Replication of such potential associations, in statistically well-powered studies, is essential to substantiate the initial findings. Therefore, we aimed specifically at replicating the strongest associations in the two clusters of SNPs within PKLR and NOS1AP, which are rs3020781 and rs7538490, respectively. However, we did not show any association with T2D for either

Table 2: Quantitative metabolic characteristics of 5,590 and 5,630 treatment-naïve individuals from the population-based Inter99 cohort, stratified according to the *PKLR* rs3020781 genotype and the *NOS1AP* rs7538490 genotype, respectively

	<i>PKLR</i> rs3020781			<i>p</i> _{Add}	<i>NOS1AP</i> rs7538490			<i>p</i> _{Dom}
	TT	TC	CC		CC	CT	TT	
<i>n</i> (men/women)	3,065 (1,544/1,521)	2,169 (1,062/1,107)	356 (180/176)		2,954 (1,474/1,480)	2,238 (1,109/1,129)	438 (221/217)	
Age (years)	46 ± 8	46 ± 8	45 ± 8		46 ± 8	46 ± 8	46 ± 8	
BMI (kg/m ²)	26.2 ± 4.6	26.2 ± 4.5	25.9 ± 4.3	0.58	26.2 ± 4.5	26.3 ± 4.6	26.1 ± 4.6	0.52
Plasma glucose (mmol/l)								
Fasting	5.5 ± 0.8	5.6 ± 0.9	5.5 ± 0.6	0.88	5.5 ± 0.7	5.5 ± 0.8	5.6 ± 1.1	0.46
30-min	8.7 ± 1.9	8.7 ± 1.9	8.6 ± 1.9	0.31	8.7 ± 1.9	8.7 ± 1.9	8.7 ± 1.8	0.90
120-min	6.2 ± 2.2	6.2 ± 2.1	6 ± 2.0	0.33	6.2 ± 2.1	6.2 ± 2.2	6.3 ± 2.1	0.22
Serum insulin (pmol/l)								
Fasting	34 (23–50)	35 (24–52)	31 (24–47)	0.21	34 (24–51)	34 (23–51)	34 (24–51)	0.14
30-min	243 (173–350)	248 (177–355)	246 (176–355)	0.29	244 (175–351)	247 (176–354)	248 (173–360)	0.67
120-min	154 (93–253)	161 (99–258)	150 (91–234)	0.45	155 (95–251)	157 (97–257)	158 (103–256)	0.59
Derived indices								
BIGTT-S _i	9.2 (6.4–12.1)	9.1 (6.2–11.9)	9.8 (7.1–12.4)	0.54	9.2 (6.5–12.1)	9.2 (6.2–12.1)	9.6 (6.0–12.1)	0.37
BIGTT-AIR	1,622 (1,282–2,083)	1,625 (1,290–2,058)	1,634 (1,280–2,092)	0.84	1,618 (1,276–2,048)	1,643 (1,301–2,118)	1,632 (1,310–2,125)	0.05
HOMA-IR	8.2 (5.6–12.6)	8.5 (5.7–13.4)	7.7 (5.5–11.4)	0.24	8.3 (5.7–12.9)	8.4 (5.5–13.1)	8.0 (5.6–12.6)	0.14

Data are means ± standard deviation or median (interquartile range). Values of plasma glucose, serum insulin, HOMA-IR and BIGTT-AIR were logarithmically transformed before statistical analysis to obtain normal distribution. All analyses of *PKLR* rs3020781 were made using an additive model (Add), while analyses of *NOS1AP* rs7539480 were made using a dominant model. Calculated *p*-values were adjusted for age and sex for BMI measures, for sex, age and BMI for serum insulin, plasma glucose and HOMA-IR, and for age for the BIGTT-S_i and BIGTT-AIR index. HOMA-IR was calculated as fasting plasma glucose (mmol/l) multiplied by fasting serum insulin (pmol/l) divided by 22.5. BIGTT-S_i and BIGTT-AIR were calculated as described [26].

of the two variants, despite having the statistical power to detect the reported effect sizes. Neither did we find an association with pertinent metabolic phenotypes, which could indicate an impaired blood glucose regulation ultimately leading to T2D.

From our studies we can exclude rs3020781 and rs7538490 as T2D susceptibility variants in the Danish population, but *PKLR* and *NOS1AP* may still represent

true T2D susceptibility loci. That *PKLR* represents a true T2D candidate gene, is supported by a study analysing two SNPs (rs1052176 and rs1052177) within *PKLR*, both showing association with T2D and both being in perfect LD with rs3020781 according to HapMap [21]. HapMap further outlined that rs3020781 is located at the border of a LD block near a recombination hotspot. Therefore, if the LD pattern is slightly shifted in our population, compared to the populations in which association is observed,

rs3020781 may fail as a marker for the functional variant. Similar may be true for rs7538490, as LD is sparse in the region where *NOS1AP* is located. Thus, different LD patterns could explain the lack of association between rs3020781 and rs7538490 and T2D in our population.

In regards to the identification of T2D susceptibility genes, the linkage analysis, used for the identification of *PKLR* and *NOS1AP*, has been less successful due to inconsistent replication.

However, genome-wide association (GWA) studies have added to progress in finding common T2D susceptible gene variants with modest impact on diabetes risk [29-34], with the identification of non-obvious biological candidate genes and where replication have been predominantly successful [35-37]. We have investigated results of available data from GWA studies in web-based databases, but neither *PKLR* nor *NOS1AP* were among the high priority candidate genes as estimated from genome-wide significance levels [29,30]. Two markers in LD with *PKLR* rs3020781 were available in the public GWA data, however, none of these associated with T2D. No markers were available for *NOS1AP* rs7538490 [29]. The lack of association could either be due to small effect sizes, or the possibility that the variants represent false positive findings, thus explaining our failure to demonstrate an association.

Conclusion

In statistically well-powered case-control studies and in studies of pertinent quantitative phenotypes we failed to validate the proposed association of the C-allele of rs3020781 and the T-allele of rs7538490 with T2D or intermediate phenotypes.

Abbreviations

Add: additive model; AF: allele frequency; BIGTT-AIR: BIGTT acute insulin response; BIGTT-S_i: BIGTT insulin sensitivity index; BMI: body mass index; CAPON: nitric oxide synthase 1 (neuronal) adaptor protein; CI: confidence interval; Dom: dominant model; GWA: genome-wide association; HOMA-IR: homeostasis model assessment of insulin resistance; LD: linkage disequilibrium; MAF: minor allele frequency; NGT: normal glucose tolerance; OGTT: oral glucose tolerance test; OR: odds ratio; SNP: single-nucleotide polymorphism; T2D: type 2 diabetes

Competing interests

KBJ and OP hold stock in Novo Nordisk and have received lecture fees from pharmaceutical companies. All other authors declare that there is no competing interest associated with this manuscript.

Authors' contributions

The original hypothesis was conceived by CHA and MSM and approved by OP and TH. Detail planning of analyses and study design was performed by CHA, MSM and approved by OP and TH. TJ, KBJ, TL, AS, OP and TH contributed to the epidemiological part of the recruitment of study populations. CHA, MSM, KA, LH, OP and TH contributed to the preparation of study populations for statistical analyses. Statistical analyses were performed by CHA and MSM. All authors contributed the interpretation of data. The first manuscript was written by CHA and MSM and the final draft was finalised by CHA, MSM, OP and TH. All authors revised the manuscript and contributed to the discussion of the results.

Acknowledgements

The authors wish to thank A. Forman, I.-L. Wantzin and M. Stendal for technical assistance and G. Lademann for secretarial support. The study was supported by grants from the Danish Health Research Council, The European Union (EUGENE-2, grant no LSHM-CT-2004-512013), the FOOD Study Group/the Danish Ministry of Food, Agriculture and Fisheries and Ministry of Family and Consumer Affairs (grant no. 2101-05-0044), Novo Nordisk A/S Research & Development Corporate Research Affairs, the Danish Ministry of Science Technology and Innovation, the Faculty of Health Sciences of Aarhus University, the Danish Clinical Intervention Research Academy, and the Danish Diabetes Association. The ADDITION trial was supported by the National Health Services in the counties of Copenhagen, Aarhus, Ringkøbing, Ribe and South Jutland in Denmark, Danish Research Foundation for General Practice, Danish Centre for Evaluation and Health Technology Assessment, The diabetes fund of the National Board of Health, The Danish Medical Research Council, The Aarhus University Research Foundation and Novo Nordisk Foundation. Furthermore the ADDITION trial has been given unrestricted grants from Novo Nordisk A/S, Novo Nordisk Scandinavia AB, ASTRA Denmark, Pfizer Denmark, GlaxoSmithKline Pharma Denmark, SERVIER Denmark A/S and HemoCue Denmark A/S.

Additional material

Additional file 1

Supplementary table 1.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2350-9-118-S1.doc>]

Footnotes

1 EASD 2007 Abstract no. 0169 (<http://www.easd.org/easdwebfiles/annualmeeting/43rdmeeting/abstracts/documents/0169.doc>); Prokopenko I, Zeggini E, Rayner NW, Groves CJ, Hanson RL, Mitchell BD et al.

High-density association mapping and comprehensive tagging of the type 2 diabetes linkage region on chromosome 1q in 4 European populations.

References

- Das SK, Elbein SC: **The search for type 2 diabetes susceptibility loci: the chromosome 1q story.** *Curr Diab Rep* 2007, **7**:154-164.
- Das SK, Hasstedt SJ, Zhang Z, Elbein SC: **Linkage and association mapping of a chromosome 1q21-q24 type 2 diabetes susceptibility locus in northern European Caucasians.** *Diabetes* 2004, **53**:492-499.
- Elbein SC, Hoffman MD, Teng K, Leppert MF, Hasstedt SJ: **A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians.** *Diabetes* 1999, **48**:1175-1182.
- Hanson RL, Ehm MG, Pettitt DJ, Prochazka M, Thompson DB, Timberlake D, et al.: **An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians.** *Am J Hum Genet* 1998, **63**:1130-1138.
- Hanson RL, Imperatore G, Narayan KM, Roumain J, Fagot-Campagna A, Pettitt DJ, et al.: **Family and genetic studies of indices of insulin sensitivity and insulin secretion in Pima Indians.** *Diabetes Metab Res Rev* 2001, **17**:296-303.
- Hsueh WC, St Jean PL, Mitchell BD, Pollin TI, Knowler WC, Ehm MG, et al.: **Genome-wide and fine-mapping linkage studies of type 2 diabetes and glucose traits in the Old Order Amish: evidence for a new diabetes locus on chromosome 14q11 and confirmation of a locus on chromosome 1q21-q24.** *Diabetes* 2003, **52**:550-557.
- Langeveld CD, Wagenknecht LE, Rotter JJ, Williams AH, Hokanson JE, Saad MF, et al.: **Linkage of the metabolic syndrome to 1q23-q31 in Hispanic families: the Insulin Resistance Atherosclerosis Study Family Study.** *Diabetes* 2004, **53**:1170-1174.
- Meigs JB, Panhuysen CI, Myers RH, Wilson PV, Cupples LA: **A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study.** *Diabetes* 2002, **51**:833-840.
- Ng MC, So WY, Cox NJ, Lam VK, Cockram CS, Critchley JA, et al.: **Genome-wide scan for type 2 diabetes loci in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25.** *Diabetes* 2004, **53**:1609-1613.
- Ng MC, So WY, Lam VK, Cockram CS, Bell GI, Cox NJ, et al.: **Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25.** *Diabetes* 2004, **53**:2676-2683.
- Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, et al.: **Genome-wide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24.** *Am J Hum Genet* 2000, **67**:1470-1480.
- Wiltshire S, Hattersley AT, Hitman GA, Walker M, Levy JC, Sampson M, et al.: **A genome-wide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q.** *Am J Hum Genet* 2001, **69**:553-569.
- Xiang K, Wang Y, Zheng T, Jia W, Li J, Chen L, et al.: **Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24.** *Diabetes* 2004, **53**:228-234.
- Zhao JY, Xiong MM, Huang W, Wang H, Zuo J, Wu GD, et al.: **An autosomal genomic scan for loci linked to type 2 diabetes in northern Han Chinese.** *J Mol Med* 2005, **83**:209-215.
- Noguchi T, Yamada K, Yamagata K, Takenaka M, Nakajima H, Imai E, et al.: **Expression of liver type pyruvate kinase in insulinoma cells: involvement of LF-B1 (HNF1).** *Biochem Biophys Res Commun* 1991, **181**:259-264.
- Yamada K, Tanaka T, Noguchi T: **Characterization and purification of carbohydrate response element-binding protein of the rat L-type pyruvate kinase gene promoter.** *Biochem Biophys Res Commun* 1999, **257**:44-49.
- Wang H, Antinozzi PA, Hagenfeldt KA, Maechler P, Wollheim CB: **Molecular targets of a human HNF1 alpha mutation responsible for pancreatic beta-cell dysfunction.** *EMBO J* 2000, **19**:4257-4264.
- Shih DQ, Screenan S, Munoz KN, Philipson L, Pontoglio M, Yaniv M, et al.: **Loss of HNF-1alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism.** *Diabetes* 2001, **50**:2472-2480.
- Jaffrey SR, Snowman AM, Eliasson MJ, Cohen NA, Snyder SH: **CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95.** *Neuron* 1998, **20**:115-124.
- Wang H, Chu W, Das SK, Ren Q, Hasstedt SJ, Elbein SC: **Liver pyruvate kinase polymorphisms are associated with type 2 diabetes in northern European Caucasians.** *Diabetes* 2002, **51**:2861-2865.
- Hasstedt SJ, Chu WS, Das SK, Wang H, Elbein SC: **Type 2 diabetes susceptibility genes on chromosome 1q21-24.** *Ann Hum Genet* 2008, **72**:163-169.
- Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C: **A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99.** *Eur J Cardiovasc Prev Rehabil* 2003, **10**:377-386.
- Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenduttel BH, Rutten G: **The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening.** *Int J Obes Relat Metab Disord* 2000, **24**(Suppl 3):S6-11.
- World Health Organization Study Group: **Part I: Diagnosis and Classification of Diabetes Mellitus.** In *Tech. Rep. Ser., no. WHO/NCD/INCS/99.2* World Health Organization, Geneva; 1999.
- Glumer C, Jorgensen T, Borch-Johnsen K: **Prevalence of diabetes and impaired glucose regulation in a Danish population: the Inter99 study.** *Diabetes Care* 2003, **26**:2335-2340.
- Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Volund A, Borch-Johnsen K, et al.: **The BIGTT test: a novel test for simultaneous measurement of pancreatic beta-cell function, insulin sensitivity, and glucose tolerance.** *Diabetes Care* 2007, **30**:257-262.
- Benyamin B, Sorensen TI, Schousboe K, Fenger M, Visscher PM, Kyvik KO: **Are there common genetic and environmental factors behind the endophenotypes associated with the metabolic syndrome?** *Diabetologia* 2007, **50**:1880-1888.
- R Development Core Team: **R: A language and environment for statistical computing, R.** 2008 [<http://www.R-project.org>]. Foundation for Statistical Computing, Vienna, Australia
- Saxena R, Voight BF, Lyssenko V, Burt NP, de Bakker PI, Chen H, et al.: **Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.** *Science* 2007, **316**:1331-1336.
- The Wellcome Trust Case Control Consortium: **Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.** *Nature* 2007, **447**:661-678.
- Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al.: **A genome-wide association study identifies novel risk loci for type 2 diabetes.** *Nature* 2007, **445**:881-885.
- Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, et al.: **A variant in CDKAL1 influences insulin response and risk of type 2 diabetes.** *Nat Genet* 2007, **39**:770-775.
- Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al.: **A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.** *Science* 2007, **316**:1341-1345.
- Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al.: **Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.** *Science* 2007, **316**:1336-1341.
- Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, Albrechtsen A, et al.: **Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies.** *Diabetes* 2007, **56**:3105-3111.
- Sparso T, Andersen G, Nielsen T, Burgdorf KS, Gjesing AP, Nielsen AL, et al.: **The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting**

and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. *Diabetologia* 2008, **51**:70-75.

37. Andreasen CH, Stender-Petersen KL, Mogensen MS, Torekov SS, Wegner L, Andersen G, et al.: **Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation.** *Diabetes* 2008, **57**:95-101.
38. Prokopenko I, Zeggini E, Rayner NW, Groves CJ, Hanson RL, Mitchell BD, et al.: **High-density association mapping and comprehensive tagging of the type 2 diabetes linkage region on chromosome 1q in 4 European populations.** *EASD 2007 Abstract no. 0169* [<http://www.easd.org/easdwebfiles/annualmeeting/43rdmeeting/abstracts/documents/0169.doc>].

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2350/9/118/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

